HealthCare Global Enterprises

KKR's Entry Will Enable Expansion Of Precision Oncology And Fertility Services

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

24 Jan 25

Updated

05 Dec 25

Views

30

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

36.6%

7D

3.3%

Loading

1Y

36.6%

7D

3.3%

You can edit this narrative until Dec 6 12:10 PM. Then, changes will post as Updates.

Author's Valuation

₹773.716.7% undervalued

AnalystConsensusTarget Fair Value

Shared on 05 Dec 25

Fair value Increased 12%

HCG: Fair Outlook Will Reflect Margin Gains And Governance Developments

Analysts have raised their price target on HealthCare Global Enterprises by approximately ₹81 to reflect slightly faster expected revenue growth, improved profit margins, and a modestly lower future price to earnings multiple in their updated valuation model. What's in the News The board has scheduled a meeting for December 01, 2025, to formally appoint Chief Internal Auditor Vijay S Shanbhag as Internal Auditor for a 6 month term under Section 138 of the Companies Act, 2013 (board filing).

Shared on 04 Aug 25

Fair value Increased 22%

The modest increases in both net profit margin and future P/E suggest improved profitability and sustained growth expectations for HealthCare Global Enterprises, supporting the upward revision of the consensus analyst price target from ₹567.29 to ₹603.88. What's in the News KKR Asian Fund IV SCSp, managed by KKR & Co. Inc., and KIA EBT II Scheme 1 completed the acquisition of a 50.4% stake in HealthCare Global Enterprises Limited from Aceso Company Pte Ltd for INR 34.28 billion, with regulatory approvals secured.

Shared on 01 May 25

Fair value Increased 1.11%

Shared on 23 Apr 25

Fair value Increased 2.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.79%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 7.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Decreased 0.72%

AnalystConsensusTarget Fair Value

₹773.71

6.7% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

14.04%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.76%

Calculation

₹3.37b

Earnings '28

x

46.71x

PE Ratio '28

=

₹157.51b

Market Cap '28

₹157.51b

Market Cap '28

/

142.25m

No. shares '28

=

₹1.11k

Share Price '28

₹1.11k Share Price '28

Discounted to 2025 @ 12.76% p.a.

=

₹772.34

Fair Value '25